Search Results - "SCHAFER, Peter H"

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus by Merrill, Joan T, Werth, Victoria P, Furie, Richard, van Vollenhoven, Ronald, Dörner, Thomas, Petronijevic, Milan, Velasco, Jorge, Majdan, Maria, Irazoque-Palazuelos, Fedra, Weiswasser, Michael, Korish, Shimon, Ye, Ying, Gaudy, Allison, Schafer, Peter H, Liu, Zhaohui, Agafonova, Nataliya, Delev, Nikolay

“…In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred…”
Get full text

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus by Schafer, Peter H, Ye, Ying, Wu, Lei, Kosek, Jolanta, Ringheim, Garth, Yang, Zhihong, Liu, Liangang, Thomas, Michael, Palmisano, Maria, Chopra, Rajesh

“…and encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220),…”
Get more information

Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex by Schafer, Peter H., Truzzi, Francesca, Parton, Anastasia, Wu, Lei, Kosek, Jolanta, Zhang, Ling-Hua, Horan, Gerald, Saltari, Annalisa, Quadri, Marika, Lotti, Roberta, Marconi, Alessandra, Pincelli, Carlo

“…Phosphodiesterases 4 (PDE4) act as proinflammatory enzymes via degradation of cAMP, whereas PDE4 inhibitors play an anti-inflammatory role in vitro and in…”
Get full text

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL by Hagner, Patrick R., Man, Hon-Wah, Fontanillo, Celia, Wang, Maria, Couto, Suzana, Breider, Mike, Bjorklund, Chad, Havens, Courtney G., Lu, Gang, Rychak, Emily, Raymon, Heather, Narla, Rama Krishna, Barnes, Leo, Khambatta, Gody, Chiu, Hsiling, Kosek, Jolanta, Kang, Jian, Amantangelo, Michael D., Waldman, Michelle, Lopez-Girona, Antonia, Cai, Ti, Pourdehnad, Michael, Trotter, Matthew, Daniel, Thomas O., Schafer, Peter H., Klippel, Anke, Thakurta, Anjan, Chopra, Rajesh, Gandhi, Anita K.

“…Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and…”
Get full text

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity by Nakayama, Yumi, Kosek, Jolanta, Capone, Lori, Hur, Eun Mi, Schafer, Peter H, Ringheim, Garth E

“…BAFF is a B cell survival and maturation factor implicated in the pathogenesis of systemic lupus erythematosus (SLE). In this in vitro study, we describe that…”
Get full text

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) by Wang, Andrew, Fang, Lorraine, Chen, Peng, Schafer, Peter H., Chopra, Rajesh

“…Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic…”
Get full text

Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response by Lopez‐Girona, Antonia, Heintel, Daniel, Zhang, Ling‐Hua, Mendy, Derek, Gaidarova, Svetlana, Brady, Helen, Bartlett, Justin Blake, Schafer, Peter H., Schreder, Martin, Bolomsky, Arnold, Hilgarth, Bernadette, Zojer, Niklas, Gisslinger, Heinz, Ludwig, Heinz, Daniel, Tom, Jäger, Ulrich, Chopra, Rajesh

“…Summary Overexpression of the transcription factor interferon regulatory factor‐4 (IRF4), which is common in multiple myeloma (MM), is associated with poor…”
Get full text

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity by Gandhi, Anita K., Mendy, Derek, Waldman, Michelle, Chen, Gengxin, Rychak, Emily, Miller, Karen, Gaidarova, Svetlana, Ren, Yan, Wang, Maria, Breider, Michael, Carmel, Gilles, Mahmoudi, Afshin, Jackson, Pilgrim, Abbasian, Mahan, Cathers, Brian E., Schafer, Peter H., Daniel, Tom O., Lopez‐Girona, Antonia, Thakurta, Anjan, Chopra, Rajesh

“…Summary Cereblon, a member of the cullin 4 ring ligase complex (CRL4), is the molecular target of the immunomodulatory drugs (IMiDs) lenalidomide and…”
Get full text

Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4 + Foxp3 + Regulatory T Cells Differentiation by Chen, Weiqian, Wang, Julie, Xu, Zhenjian, Huang, Feng, Qian, Wenbin, Ma, Jilin, Wee, Hwa Bok, Lewis, Gregory S, June, Rayford R, Schafer, Peter H, Lin, Jin, Zheng, Song Guo

“…Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor suppressing immune and inflammatory responses. We assessed the anti-inflammatory effects of…”
Get full text

Novel systemic drugs for psoriasis: Mechanism of action for apremilast, a specific inhibitor of PDE4 by Schafer, Peter H., PhD, Day, Robert M., PhD

Get full text

Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice by Schafer, Peter H., Adams, Mary, Horan, Gerald, Truzzi, Francesca, Marconi, Alessandra, Pincelli, Carlo

“…Background Apremilast, an oral phosphodiesterase (PDE) 4 inhibitor, has demonstrated efficacy in psoriasis, while its efficacy in atopic dermatitis (AD) was…”
Get full text

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study by Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.

“…Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc…”
Get full text

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells by VERHELLE, Dominique, CORRAL, Laura G, LOPEZ-GIRONA, Antonia, MUTTER, George W, BRADY, Helen A, CHAN, Kyle W. H, WONG, Kevin, MUELLER, Jessica H, MOUTOUH-DE PARSEVAL, Laure, JENSEN-PERGAKES, Kristen, SCHAFER, Peter H, CHEN, Roger, GLEZER, Emilia, FERGUSON, Gregory D

“…Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often…”
Get full text

Prognostic Significance and Biologic Associations of Senescence-Associated Secretory Phenotype Biomarkers in Heart Failure by Salman, Oday, Zamani, Payman, Zhao, Lei, Dib, Marie Joe, Gan, Sushrima, Azzo, Joe David, Pourmussa, Bianca, Richards, Arthur Mark, Javaheri, Ali, Mann, Douglas L, Rietzschel, Ernst, Zhao, Manyun, Wang, Zhaoqing, Ebert, Christina, Liu, Laura, Gunawardhana, Kushan L, Greenawalt, Danielle, Carayannopoulos, Leon, Chang, Ching-Pin, van Empel, Vanessa, Gogain, Joseph, Schafer, Peter H, Gordon, David A, Ramirez-Valle, Francisco, Cappola, Thomas P, Chirinos, Julio A

“…The role of cellular senescence in human heart failure (HF) remains unclear. The senescence-associated secretory phenotype (SASP) is composed of proteins…”
Get full text

Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure With Preserved Ejection Fraction by Salman, Oday, Zhao, Lei, Cohen, Jordana B, Dib, Marie Joe, Azzo, Joe David, Gan, Sushrima, Richards, A Mark, Pourmussa, Bianca, Doughty, Rob, Javaheri, Ali, Mann, Douglas L, Rietzschel, Ernst, Zhao, Manyun, Wang, Zhaoqing, Ebert, Christina, van Empel, Vanessa, Kammerhoff, Karl, Maranville, Joseph, Gogain, Joseph, Dennis, Jaclyn, Schafer, Peter H, Seiffert, Dietmar, Gordon, David A, Ramirez-Valle, Francisco, Cappola, Thomas P, Chirinos, Julio A

“…Kidney disease is common in heart failure with preserved ejection fraction (HFpEF). However, the biologic correlates and prognostic significance of kidney…”
Get full text

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study by Furie, Richard A, Hough, Douglas R, Gaudy, Allison, Ye, Ying, Korish, Shimon, Delev, Nikolay, Weiswasser, Michael, Zhan, Xiaojiang, Schafer, Peter H, Werth, Victoria P

“…ObjectiveTo evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand…”
Get full text

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions by Lu, Ling, Payvandi, Faribourz, Wu, Lei, Zhang, Ling-Hua, Hariri, Robert J, Man, Hon-Wah, Chen, Roger S., Muller, George W., Hughes, Christopher C.W., Stirling, David I., Schafer, Peter H., Bartlett, J. Blake

“…Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic…”
Get full text

Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction by Carland, Corinne, Zhao, Lei, Salman, Oday, Cohen, Jordana B, Zamani, Payman, Xiao, Qing, Dongre, Ashok, Wang, Zhaoqing, Ebert, Christina, Greenawalt, Danielle, van Empel, Vanessa, Richards, A Mark, Doughty, Robert N, Rietzschel, Ernst, Javaheri, Ali, Wang, Yixin, Schafer, Peter H, Hersey, Sarah, Carayannopoulos, Leonidas N, Seiffert, Dietmar, Chang, Ching-Pin, Gordon, David A, Ramirez-Valle, Francisco, Mann, Douglas L, Cappola, Thomas P, Chirinos, Julio A

“…Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value…”
Get full text

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients by Gandhi, Anita K, Shi, Tao, Li, Mingyu, Jungnelius, Ulf, Romano, Alfredo, Tabernero, Josep, Siena, Salvatore, Schafer, Peter H, Chopra, Rajesh

“…This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II…”
Get full text

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers by van der Velden, Jos L. J., Ye, Ying, Nolin, James D., Hoffman, Sidra M., Chapman, David G., Lahue, Karolyn G., Abdalla, Sarah, Chen, Peng, Liu, Yong, Bennett, Brydon, Khalil, Nasreen, Sutherland, Donna, Smith, William, Horan, Gerald, Assaf, Mahmoud, Horowitz, Zebulun, Chopra, Rajesh, Stevens, Randall M., Palmisano, Maria, Janssen-Heininger, Yvonne M. W., Schafer, Peter H.

“…Background Lung remodeling and pulmonary fibrosis are serious, life-threatening conditions resulting from diseases such as chronic severe asthma and idiopathic…”
Get full text